Suresh Katragadda

BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A

Barbara A. Konkle, Amy D. Shapiro, Doris Quon et al. · New England Journal of Medicine · 2020 · 126 citations · Full text

Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study

Toshko Lissitchkov, Annemieke Willemze, Suresh Katragadda et al. · Blood Advances · 2021 · 39 citations · Full text

Thrombosis, Antibiotics, Clinical Epidemiology +14

Pharmacokinetics of recombinant factor VIII in adults with severe hemophilia A: fixed-sequence single-dose study of octocog alfa, rurioctocog alfa pegol, and efanesoctocog alfa

Toshko Lissitchkov, Annemieke Willemze, Christelle Jan et al. · Research and Practice in Thrombosis and Haemostasis · 2023 · 18 citations · Full text

BIVV001: The First Investigational Factor VIII Therapy to Break Through the VWF Ceiling in Hemophilia A, with Potential for Extended Protection for One Week or Longer

Barbara A. Konkle, Amy D. Shapiro, Doris Quon et al. · Blood · 2018 · 13 citations